FDA shuns Rocket's immune disorder gene therapy over manufacturing shortcomings

The FDA has rejected Rocket Pharmaceutical's gene therapy Kresladi for severe leukocyte adhesion deficiency-I due to manufacturing concerns. This delay impacts approval timeline and voucher eligibility. Rocket aims to provide requested information promptly to move forward.